Article Information
History
- January 4, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Denisa Bojkova1,
- Marek Widera1,
- Sandra Ciesek1,2,3,
- Mark N. Wass4,*,
- Martin Michaelis4,* and
- Jindrich Cinatl jr.1,5,*
- 1Institute for Medical Virology, University Hospital, Goethe University, Frankfurt am Main, Germany
- 2German Center for Infection Research, DZIF, External partner site Frankfurt am Main, Germany
- 3Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Branch Translational Medicine und Pharmacology, Frankfurt am Main, Germany
- 4School of Biosciences, University of Kent, Canterbury, UK
- 5Dr. Petra Joh-Forschungshaus, Frankfurt am Main, Germany
- ↵*Corresponding authors: Jindrich Cinatl jr., Institute for Medical Virology, University Hospital, Goethe University, Paul Ehrlich-Straße 40, 60596 Frankfurt am Main, Germany; phone +49 69 6301 6409; e-mail Cinatl{at}em.uni-frankfurt.de, Martin Michaelis, School of Biosciences, University of Kent, Canterbury CT2 7NJ, UK; phone +44 1227 82 7804; e-mail M.Michaelis{at}kent.ac.uk, Mark N. Wass, School of Biosciences, University of Kent, Canterbury CT2 7NJ, UK; phone +44 1227 82 7626; e-mail M.N.Wass{at}kent.ac.uk
Posted January 04, 2022.
Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates
